T-cell receptor recognizing glioma stem cell antigen–major histocompatibility complex complex (TCR)

The **T-cell receptor (TCR) recognizing glioma stem cell (GSC) antigens on the major histocompatibility complex (MHC)** refers to a T-lymphocyte membrane receptor that is responsible for the highly specific recognition of peptides derived from GSC-associated tumor antigens presented by MHC (often class I on tumor cells or class II on antigen-presenting cells)[4][6][7]. The interaction between a TCR and its specific peptide–MHC combination is key to initiating T-cell activation, signaling, and cytotoxic response against tumor cells. Each TCR is unique for a given antigenic peptide–MHC complex, with specificity determined by somatic recombination in the TCR α and β chains[4][6]. When used as a therapeutic target, this class of receptors forms the basis of adoptive T-cell therapies (TCR-T), where T cells are genetically engineered to express TCRs that recognize tumor-specific or tumor-associated antigens (e.g., overexpressed or mutant proteins) present on glioma stem cells in the context of a particular MHC molecule. The main challenges include specificity (avoiding recognition of healthy tissue peptides), antigen presentation/loss by tumor, and safety management of on- and off-tumor responses. **Note:** Further structuring requires specification of the exact TCR and GSC antigen (e.g., "T-cell receptor recognizing EGFRvIII on HLA-A*02:01") for precise mapping to existing biological databases[4][6][7][3][1].

Other names

T-cell antigen receptor specific for glioma stem cell antigen–MHC complexTCR targeting GSC antigensAntigen-specific T-cell receptor (if GSC antigen defined)

Antigen-specific recognition and activation of T cells through engagement of cognate peptide–MHC complex on glioma stem cells, triggering cytotoxicity or cytokine release. For engineered therapies: adoptive transfer of T cells with TCRs engineered to recognize GSC antigen/MHC, resulting in targeted lysis of tumor cells.